Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.11. | Santen, Arctic Vision sign deal for ARVN001 to treat UME | 1 | Pharmaceutical Technology | ||
07.11. | Clearside Biomedical, Inc.: Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy ... | 85 | GlobeNewswire (Europe) | - Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space... ► Artikel lesen | |
21.10. | NICE recommends Santen's Roclanda to treat glaucoma and ocular hypertension | 10 | PharmaTimes | ||
06.08. | Santen and Cloudbreak enter licence agreement for pterygium treatment | 3 | Pharmaceutical Business Review | ||
SANTEN PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
06.08. | Santen Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34B | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVARTIS | 93,29 | 0,00 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 100 Schweizer Franken auf "Hold" belassen. Dies schrieb der Analyst Emmanuel Papadakis in... ► Artikel lesen | |
MPH HEALTH CARE | 22,800 | +0,88 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen / Kursziel: EUR 108 | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH 18.12.2024 / 15:36 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer... ► Artikel lesen | |
HIGH TIDE | 2,885 | -0,17 % | High Tide eröffnet zwei neue Canna Cabana-Läden in Alberta bzw. Ontario | Das Unternehmen beendet das Jahr 2024 mit 29 neu eröffneten Filialen in ganz Kanada
CALGARY, AB, 18. Dezember 2024 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen")... ► Artikel lesen | |
COMPASS PATHWAYS | 3,860 | +1,58 % | Compass Pathways plc: Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added... ► Artikel lesen | |
PHARMASGP | 23,600 | -6,35 % | EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.11.2024 / 12:00... ► Artikel lesen | |
SHANGHAI FOSUN PHARMACEUTICAL | 1,686 | 0,00 % | FOSUN PHARMA (02196): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | ||
SEELOS THERAPEUTICS | 2,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 24.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.10.2024ISIN NameAU0000114977 BOOKTOPIA... ► Artikel lesen | |
PROMINO NUTRITIONAL SCIENCES | 0,028 | -21,13 % | Promino Nutritional Sciences, Inc.: Promino Nutritional Sciences Inc. Provides Shareholder Progress Report | Burlington, Ontario--(Newsfile Corp. - December 11, 2024) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the "Company" or "Promino") is pleased to present a progress... ► Artikel lesen | |
SAVARA | 3,100 | -0,64 % | Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company | ||
EVOLUS | 10,300 | -0,96 % | Evolus Reports Third Quarter 2024 Results | NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results... ► Artikel lesen | |
ATYR PHARMA | 3,160 | -1,86 % | SWOT-Analyse von aTyr Pharma: Das Potenzial von Efzofitimod bestimmt die Aktienaussichten | ||
EVOKE PHARMA | 3,840 | 0,00 % | Evoke Pharma, Inc.: Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends | ||
CIPHER PHARMACEUTICALS | 9,600 | +1,59 % | Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study | ||
IMMUNOPRECISE ANTIBODIES | 0,386 | -7,66 % | ImmunoPrecise Antibodies Ltd.: IPA to Present at The Microcap Conference 2025 | VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced... ► Artikel lesen | |
NANO MRNA | 0,780 | -3,70 % | Epoxidharz: Polydopamin-funktionalisierte g-C3N4-Nanosheets als reaktive Nanocarrier für 2-Mercaptobenzimidazol in Antikorrosionsbeschichtungen |